Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel)(Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel))

概要

基本信息

药物类型

细胞疗法

别名-

靶点-

作用机制

细胞替代物

治疗领域

肿瘤

在研适应症-

非在研适应症

实体瘤

原研机构

Universitair Ziekenhuis Brussel

在研机构-

非在研机构

Universitair Ziekenhuis Brussel

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的临床试验

NCT03707808 / Completed临床1期IIT

Phase I Clinical Trial on Intratumoral Administration of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Avelumab and Ipilimumab in Combination With Intravenously Administered Nivolumab

This phase I trial aims at investigating a new combinatorial immunotherapy regimen using intratumoral injection of autologous CD1c (BDCA-1)+ myeloid dendritic cells in combination with intratumoral injection of the CTLA-4 blocking monoclonal antibody (mAb) ipilimumab and the PD-L1 blocking mAb avelumab. Concomitantly, nivolumab (a PD-1 blocking mAb) will be administered intravenously.

开始日期2018-01-29

申办/合作机构

Universitair Ziekenhuis Brussel

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的临床结果

登录后查看更多信息

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的转化医学

登录后查看更多信息

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的专利（医药）

登录后查看更多信息

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
实体瘤	临床1期	比利时	Universitair Ziekenhuis Brussel	2018-01-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03707808 (ESMO2024) 人工标引	临床1期	难治性黑色素瘤	6	Autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with AS01B plus ipilimumab (IPI) and nivolumab (NIVO)	(淵餘蓋觸鬱壓淵餘壓構) = Treatment related adverse events (TRAE) included transient grade 1/2 injection site reactions and constitutional symptoms. One pt experienced a grade 3 systemic inflammatory syndrome with a lymphocytic peritoneal exudate (responsive to corticosteroids). There were no grade 4-5 TRAE. 糧觸憲顧積廠網衊構觸 (選窪夢獵願鹹築鏇遞壓 )	积极	2024-09-14
NCT03707808 (Pubmed) 人工标引	临床1期	难治性黑色素瘤 CD1c (BDCA-1) \| CD141 (BDCA-3)	8	autologous CD1c (BDCA-1)+ myDC+ ipilimumab + nivolumab	(襯襯簾艱淵積獵餘餘積) = 構憲範蓋繭齋積繭範鑰餘觸餘構鹹顧襯繭夢鑰 (製簾簾醖獵積簾廠糧觸 ) 更多	积极	2024-01-11
NCT03707808 (SITC2022) 人工标引	临床1期	BRAF V600 突变阳性黑色素瘤 BRAF V600	8	CD1c (BDCA-1)+/CD141 (BDCA-3)+ myDC(Universitair Ziekenhuis Brussel)+nivolumab+ipilimumab	(淵製膚積夢襯襯鏇蓋網) = 餘觸製鹽願構顧壓觸願窪繭繭築範遞醖膚憲網 (夢醖觸齋齋觸觸廠範繭, 5.193 ~ 15.007) 更多	积极	2022-11-01
NCT03707808 (ASCO2019) 人工标引	临床1期	HR阳性/HER2低表达实体瘤二线	6	ipilimumab+Avelumab+Nivolumab+Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells	(觸遞繭壓壓襯餘夢遞鹹) = transient G 2 local pain at injection site in 2 pts, G1 pruritus in 2 pts, G2 pneumonitis in 1 pt, G1 rash in 1 pt, pruritus and redness of the skin overlaying the injected lesion in 1 pt 鬱觸網醖憲鹹衊淵簾鑰 (製獵襯夢廠構觸顧鹹壓 ) 更多	积极	2019-05-31